Olanzapine as an add-on treatment in migraine status: A randomized double-blind, placebo-controlled, pilot study

• Autores: Johana Mogollón, Ana Serrano, Alix Padrón Freitez, Euderruh Uzcátegui, Trino Baptista
• Localización: European journal of psychiatry, ISSN 0213-6163, Vol. 26, Nº 4, 2012, págs. 260-265
• Idioma: inglés
• DOI: 10.4321/s0213-61632012000400005
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background and Objectives: The authors assessed the effectiveness of olanzapine as an adjunctive treatment in migraine status.

    Methods: Randomized, double-blind, placebo-controlled study. Subjects consecutively admitted to a day program of tertiary referral (97 % women; age: 35.8 �} 11.8 yrs.) were assigned to olanzapine (n = 14, 5-10 mg/day) or placebo (n = 17), added to the standard neurological treatment during 4 days. Primary measures were the change in pain and the return to regular daily activities. Secondary and safety measures were the magnitude of sedation, constipation and glucose level changes.

    Results: No significant differences were observed in the overall analysis of the primary measures. However, change in pain significantly correlated with age in the olanzapine group (p = 0.03). In the . 40 year-old group, olanzapine (n = 5) displayed a significantly higher reduction in pain than placebo (n = 4) at days 1 (p = 0.048) and 3 (p = 0.045). No significant differences were observed in the change of serum glucose levels.

    Conclusions: Olanzapine was well tolerated and sedation was welcomed by most subjects.

    The positive effect in subjects aged . 40 years awaits replication.